AB0220 What Proportion of Patients Fail To Achieve CDAI and SDAI Remission Based on Physician Global Assessment? An Analysis from A Prospective, Observational Registry

医学 Golimumab公司 类风湿性关节炎 银屑病性关节炎 英夫利昔单抗 内科学 观察研究 物理疗法 接收机工作特性 强直性脊柱炎 前瞻性队列研究 疾病 阿达木单抗
作者
Michelle C. Starr,B. Haraoui,D. Choquette,Louis Bessette,Andrew Chow,P. Baer,S. Kapur,J. Kelsall,Michelle Teo,Emmanouil Rampakakis,Eliofotisti Psaradellis,F. Nantel,A.J. Lehman,B. Osborne,K. Maslova,C.M. Tkaczyk
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:75 (Suppl 2): 973.2-973
标识
DOI:10.1136/annrheumdis-2016-eular.4801
摘要

Background

Physician9s Global Assessment of Disease Activity (MDGA) is a measure that is frequently incorporated in disease activity indices which reflects the physician9s perception of disease activity in rheumatoid arthritis (RA).

Objectives

The aim of this analysis was to assess the proportion of patients failing to achieve CDAI and SDAI remission based on MDGA in a real-world, routine clinical care setting in Canada.

Methods

BioTRAC is an ongoing, prospective registry of patients initiating treatment for RA, ankylosing spondylitis (AS), or psoriatic arthritis (PsA) with infliximab (IFX) or golimumab (GLM). Eligible patients for this analysis included RA patients treated with IFX or GLM between 2005 and 2015. Modified versions of CDAI (mCDAI) and SDAI (mSDAI) were calculated by omitting MDGA from the formulas. Correlation of the standard and modified versions of each index was assessed with the Pearson9s correlation coefficient. ROC curve analysis was used to identify new thresholds for the modified versions of low disease activity (LDA) and remission. Cross-tabulations with the Chi-square test were used to assess the agreement between the standard and modified definitions of remission and LDA.

Results

A total of 1206 patients were included in the analysis with a mean (SD) age of 56.1 (13.4) years and a disease duration of 8.4 (8.9) years. A strong positive correlation was observed between the standard and modified versions of CDAI (r=0.99; P<0.001) and SDAI (r=0.99; P<0.001). Based on ROC analysis the new thresholds for remission and LDA were: CDAI (remission=2.65, LDA=10.05) and SDAI (remission=3.31, LDA=10.73). The proportion of patients achieving remission by both indices was 17.8% and 19.5%, patients not achieving remission by both indices was 75.3% and 74.4%, and patients achieving remission by the new thresholds only was 6.9% and 6.1%, for CDAI and SDAI, respectively. Cross-tabulation of the standard and modified thresholds showed that an additional 8.4% and 7.6% of non-remission cases for CDAI and SDAI, respectively, would be classified as remission with the modified definitions. Similarly, an additional 17.6% and 15.1% of non-LDA cases for CDAI and SDAI, respectively, would be classified as LDA.

Conclusions

The results of this analysis showed that MDGA could account for up to 8% of non-remission cases and up to 18% of non-LDA cases as measured by CDAI and SDAI. Omission of MDGA from these disease activity indices could have a significant impact on patient management in preventing overtreatment with DMARDs and biologics and avoiding unnecessary switching of DMARDs and biologics.

Disclosure of Interest

M. Starr: None declared, B. Haraoui: None declared, D. Choquette: None declared, L. Bessette: None declared, A. Chow: None declared, P. Baer: None declared, S. Kapur: None declared, J. Kelsall: None declared, M. Teo: None declared, E. Rampakakis Employee of: JSS, E. Psaradellis Employee of: JSS, F. Nantel Employee of: Janssen, A. Lehman Employee of: Janssen, B. Osborne Employee of: Janssen, K. Maslova Employee of: Janssen, C. Tkaczyk Employee of: Janssen

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
毕了个毕发布了新的文献求助10
刚刚
刚刚
1秒前
molihuakai的应助被茂飞采纳,获得10
1秒前
1秒前
beryl完成签到,获得积分10
2秒前
xhj666发布了新的文献求助10
2秒前
123发布了新的文献求助10
2秒前
zwq发布了新的文献求助10
3秒前
3秒前
3秒前
所所的应助被科研通管家采纳,获得10
3秒前
自由的尔槐完成签到,获得积分10
3秒前
wu完成签到 ,获得积分10
3秒前
molihuakai的应助被科研通管家采纳,获得10
3秒前
包语梦发布了新的文献求助10
3秒前
桐桐的应助被科研通管家采纳,获得10
3秒前
搜集达人的应助被科研通管家采纳,获得10
4秒前
Hello的应助被科研通管家采纳,获得10
4秒前
鱼棒棒完成签到,获得积分10
4秒前
FashionBoy的应助被科研通管家采纳,获得10
4秒前
4秒前
CodeCraft的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
CodeCraft的应助被29采纳,获得10
4秒前
华仔的应助被科研通管家采纳,获得10
4秒前
李爱国的应助被科研通管家采纳,获得10
5秒前
斯文败类的应助被4ll采纳,获得10
5秒前
orixero的应助被科研通管家采纳,获得10
5秒前
思源的应助被科研通管家采纳,获得10
5秒前
科目三的应助被科研通管家采纳,获得10
5秒前
赘婿的应助被科研通管家采纳,获得10
5秒前
彭于晏的应助被科研通管家采纳,获得10
5秒前
高大的映波完成签到 ,获得积分10
5秒前
脑洞疼的应助被科研通管家采纳,获得10
5秒前
桐桐的应助被科研通管家采纳,获得10
5秒前
丘比特的应助被科研通管家采纳,获得10
6秒前
张灬小胖发布了新的文献求助10
6秒前
大模型的应助被科研通管家采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171477
求助须知:如何正确求助?哪些是违规求助? 9564248
关于积分的说明 21774106
捐赠科研通 7763073
什么是DOI,文献DOI怎么找? 3430972
关于科研通互助平台的介绍 2554805
邀请新用户注册赠送积分活动 2475887